Gene therapy progress and prospects: Novel gene therapy approaches for AIDS (original) (raw)

• Blesch A . Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer. Methods 2004; 33: 164–172.
  CAS PubMed Google Scholar
• Muhlebach MD et al. Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes. J Mol Med 2003; 81: 801–810.
  PubMed Google Scholar
• An DS et al. Efficient lentiviral vectors for short hairpin RNA delivery into human cells. Hum Gene Ther 2003; 14: 1207–1212.
  CAS PubMed Google Scholar
• Mautino MR, Morgan RA . Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genes. AIDS Patient Care STDS 2002; 16: 11–26.
  PubMed Google Scholar
• Trono D . Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Therapy 2000; 7: 20–23.
  CAS PubMed Google Scholar
• Connolly JB . Lentiviruses in gene therapy clinical research. Gene Therapy 2002; 9: 1730–1734.
  CAS PubMed Google Scholar
• Duprâe L et al. Lentiviral vector-mediated gene transfer in T cells from Wiskott–Aldrich syndrome patients leads to functional correction. Mol Ther: J Am Soci Gene Therapy 2004; 10: 903–915.
  Google Scholar
• Kurre P et al. Efficient marking of murine long-term repopulating stem cells targeting unseparated marrow cells at low lentiviral vector particle concentration. Mol Ther: J Am Soci Gene Therapy 2004; 9: 914–922.
  CAS Google Scholar
• Miyoshi H . Subteam for Manipulation of Cell Fate, Gene delivery to hematopoietic stem cells using lentiviral vectors. Meth Mol Biol (Clifton, N.J.) 2004; 246: 429–438.
  CAS Google Scholar
• Stitz J et al. A novel lentivirus vector derived from apathogenic simian immunodeficiency virus. Virology 2001; 291: 191–197.
  CAS PubMed Google Scholar
• Curran MA et al. Efficient transduction of pancreatic islets by feline immunodeficiency virus vectors1. Transplantation 2002; 74: 299–306.
  CAS PubMed Google Scholar
• Poeschla EM . Non-primate lentiviral vectors. Curr Opin Mol Ther 2003; 5: 529–540.
  CAS PubMed Google Scholar
• Saenz DT, Poeschla EM . FIV: from lentivirus to lentivector. J Gene Med 2004; 6 (Suppl 1): S95–S104.
  CAS PubMed Google Scholar
• Luis Abad J et al. Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol Ther 2003; 8: 475–484.
  PubMed Google Scholar
• Venkatesan S et al. Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration. J Biol Chem 2002; 277: 2287–2301.
  CAS PubMed Google Scholar
• Yang S, Sun Y, Zhang H . The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J Biol Chem 2001; 276: 4889–4893.
  CAS PubMed Google Scholar
• Yang B et al. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J Biol Chem 2003; 278: 6596–6602.
  CAS PubMed Google Scholar
• Hrimech M et al. Human immunodeficiency virus type 1 Vpr-mediated G(2) cell cycle arrest: Vpr interferes with cell cycle signaling cascades by interacting with the B subunit of serine/threonine protein phosphatase 2A. EMBO J 2002; 21: 3918.
  CAS PubMed Google Scholar
• Elder RT et al. HIV-1 VPR modulates cell cycle G2/M transition through an alternative cellular mechanism other than the classic mitotic checkpoints. Front Biosci: J Virtual Library 2002; 7: d349–d357.
  CAS Google Scholar
• Sawaya BE et al. Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73. J Virol 2000; 74: 4877–4881.
  CAS PubMed PubMed Central Google Scholar
• Yung E et al. Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nat Med 2001; 7: 920–926.
  CAS PubMed Google Scholar
• Cordelier P, Zern MA, Strayer DS . HIV-1 proprotein processing as a target for gene therapy. Gene Therapy 2003; 10: 467–477.
  CAS PubMed Google Scholar
• Cordelier P et al. Inhibiting AIDS in the central nervous system: gene delivery to protect neurons from HIV. Molecular Ther: J Am Soci Gene Therapy 2003; 7: 801–810.
  CAS Google Scholar
• Goncalves J et al. Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J Biol Chem 2002; 277: 32036–32045.
  CAS PubMed Google Scholar
• Tewari D, Notkins AL, Zhou P . Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene. J Gene Med 2003; 5: 182–189.
  CAS PubMed Google Scholar
• Herschhorn A, Admon A, Hizi A . Recombinant human antibodies against the reverse transcriptase of human immunodeficiency virus type-1. Biochim Biophys Acta 2003; 1648: 154–163.
  CAS PubMed Google Scholar
• BouHamdan M et al. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4. Gene Therapy 2001; 8: 408–418.
  CAS PubMed Google Scholar
• Bai J et al. Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem 2003; 278: 1433–1442.
  CAS PubMed Google Scholar
• Reynolds L et al. Repression of the HIV-1 5′ LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors. Proc Natl Acad Sci USA 2003; 100: 1615–1620.
  CAS PubMed PubMed Central Google Scholar
• Segal DJ et al. Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J Biol Chem 2004; 279: 14509–14519.
  CAS PubMed Google Scholar
• Takada N et al. RelA-associated inhibitor blocks transcription of human immunodeficiency virus type 1 by inhibiting NF-kappaB and Sp1 actions. J Virol 2002; 76: 8019–8030.
  CAS PubMed PubMed Central Google Scholar
• Michienzi A et al. RNA-mediated inhibition of HIV in a gene therapy setting. Ann NY Acad Sci 2003; 1002: 63–71.
  CAS PubMed Google Scholar
• Puerta-Fernandez E, Barroso-DelJesus A, Berzal-Herranz A . Anchoring hairpin ribozymes to long target RNAs by loop-loop RNA interactions. Antisense Nucleic Acid Drug Dev 2002; 12: 1–9.
  CAS PubMed Google Scholar
• Puerta-Fernandez E et al. HIV-1 TAR as anchoring site for optimized catalytic RNAs. Biol Chem 2003; 384: 343–350.
  CAS PubMed Google Scholar
• Ramezani A et al. Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1. Front Biosci 2002; 7: a29–a36.
  CAS PubMed Google Scholar
• Jacque JM, Triques K, Stevenson M . Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435–438.
  CAS PubMed Google Scholar
• Paul CP et al. Localized expression of small RNA inhibitors in human cells. Mol Ther: J Am Soci Gene Therapy 2003; 7: 237–247.
  CAS Google Scholar
• Lee NS et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002; 20: 500–505.
  CAS PubMed Google Scholar
• Coburn GA, Cullen BR . Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol 2002; 76: 9225–9231.
  CAS PubMed PubMed Central Google Scholar
• Boden D et al. Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003; 77: 11531–11535.
  CAS PubMed PubMed Central Google Scholar
• Das AT et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004; 78: 2601–2605.
  CAS PubMed PubMed Central Google Scholar
• Chiu YL et al. Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol 2004; 78: 2517–2529.
  CAS PubMed PubMed Central Google Scholar
• Cen S et al. Incorporation of lysyl-tRNA synthetase into human immunodeficiency virus type 1. J Virol 2001; 75: 5043–5048.
  CAS PubMed PubMed Central Google Scholar
• Guo F et al. Specific inhibition of the synthesis of human lysyl-tRNA synthetase results in decreases in tRNA(Lys) incorporation, tRNA(3)(Lys) annealing to viral RNA, and viral infectivity in human immunodeficiency virus type 1. J Virol 2003; 77: 9817–9822.
  CAS PubMed PubMed Central Google Scholar
• Anderson J et al. Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res Hum Retroviruses 2003; 19: 699–706.
  CAS PubMed Google Scholar
• Park WS et al. Specific HIV-1 env gene silencing by small interfering RNAs in human peripheral blood mononuclear cells. Gene Therapy 2003; 10: 2046–2050.
  CAS PubMed Google Scholar
• Lee MT et al. Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol 2003; 77: 11964–11972.
  CAS PubMed PubMed Central Google Scholar
• Li MJ et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther: J Am Soci Gene Therapy 2003; 8: 196–206.
  CAS Google Scholar
• Akkina R et al. siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Anticancer Res 2003; 23: 1997–2005.
  CAS PubMed Google Scholar
• Eckert DM, Kim PS . Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001; 70: 777–810.
  CAS PubMed Google Scholar
• Carr A . Toxicity of antiretroviral therapy and implications for drug development. Nature reviews. Drug Discov 2003; 2: 624–634.
  CAS Google Scholar
• Baldwin CE, Sanders RW, Berkhout B . Inhibiting HIV-1 entry with fusion inhibitors. Curr Med Chem 2003; 10: 1633–1642.
  CAS PubMed Google Scholar
• Hildinger M et al. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol 2001; 75: 3038–3042.
  CAS PubMed PubMed Central Google Scholar
• Egelhofer M et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 2004; 78: 568–575.
  CAS PubMed PubMed Central Google Scholar
• Baldwin CE et al. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 2004; 78: 12428–12437.
  CAS PubMed PubMed Central Google Scholar
• Mergia A et al. The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs. Virology 2001; 280: 243–252.
  CAS PubMed Google Scholar
• Garrus JE et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001; 107: 55–65.
  CAS PubMed Google Scholar
• Perez OD, Nolan GP . Resistance is futile: assimilation of cellular machinery by HIV-1. Immunity 2001; 15: 687–690.
  CAS PubMed Google Scholar
• Demirov DG et al. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci USA 2002; 99: 955–960.
  CAS PubMed PubMed Central Google Scholar
• Martin-Serrano J, Zang T, Bieniasz PD . Role of ESCRT-I in retroviral budding. J Virol 2003; 77: 4794–4804.
  CAS PubMed PubMed Central Google Scholar
• von Schwedler UK et al. The protein network of HIV budding. Cell 2003; 114: 701–713.
  CAS PubMed Google Scholar
• Strack B et al. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 2003; 114: 689–699.
  CAS PubMed Google Scholar
• Ono A, Freed EO . Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol 2004; 78: 1552–1563.
  CAS PubMed PubMed Central Google Scholar
• Chakraborti S, Banerjea AC . Inhibition of HIV-1 gene expression by novel DNA enzymes targeted to cleave HIV-1 TAR RNA: potential effectiveness against all HIV-1 isolates. Mol Ther 2003; 7: 817–826.
  CAS PubMed Google Scholar
• Joshi PJ, Fisher TS, Prasad VR . Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Curr Drug Targets Infect Disord 2003; 3: 383–400.
  CAS PubMed Google Scholar
• Xu X et al. Dominant effector genetics in mammalian cells. Nat Genet 2001; 27: 23–29.
  CAS PubMed Google Scholar
• Wolkowicz R, Nolan GP . Retroviral technology—applications for expressed peptide libraries. Front Biosci 2003; 8: d603–d619.
  CAS PubMed Google Scholar
• De Clercq E, Schols D . Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists. Antivir Chem Chemother 2001; 12 (Suppl 1): 19–31.
  CAS PubMed Google Scholar
• Ruff MR et al. Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Curr HIV Res 2003; 1: 51–67.
  CAS PubMed Google Scholar
• Baraz L et al. Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region. J Gen Virol 2002; 83 (Part 9): 2225–2230.
  CAS PubMed Google Scholar
• Hutoran M et al. Abrogation of Vif function by peptide derived from the N-terminal region of the human immunodeficiency virus type 1 (HIV-1) protease. Virology 2004; 5: 261–270.
  Google Scholar
• Stremlau M et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427: 848–853.
  CAS PubMed Google Scholar
• Goff SP . HIV: replication trimmed back. Nature 2004; 427: 791–793.
  CAS PubMed Google Scholar
• Sheehy AM, Gaddis NC, Malim MH . The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003; 9: 1404–1407.
  CAS PubMed Google Scholar
• Mangeat B et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424: 99–103.
  CAS PubMed Google Scholar
• Mariani R et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003; 114: 21–31.
  CAS PubMed Google Scholar
• Stopak K et al. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003; 12: 591–601.
  CAS PubMed Google Scholar
• Marin M et al. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003; 9: 1398–1403.
  CAS PubMed Google Scholar
• Liu B et al. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol 2004; 78: 2072–2081.
  CAS PubMed PubMed Central Google Scholar
• Gabus C et al. The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein. J Mol Biol 2001; 307: 1011–1021.
  CAS PubMed Google Scholar
• Leblanc P, Baas D, Darlix JL . Analysis of the interactions between HIV-1 and the cellular prion protein in a human cell line. J Mol Biol 2004; 337: 1035–1051.
  CAS PubMed Google Scholar
• Ganesh L et al. The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature 2003; 426: 853–857.
  CAS PubMed Google Scholar
• Greene WC . How resting T cells deMURR HIV infection. Nat Immunol 2004; 5: 18–19.
  CAS PubMed Google Scholar
• Iordanskiy S et al. Heat shock protein 70 protects cells from cell cycle arrest and apoptosis induced by human immunodeficiency virus type 1 viral protein R. J Virol 2004; 78: 9697–9704.
  CAS PubMed PubMed Central Google Scholar
• Iordanskiy S et al. Heat–shock protein 70 exerts opposing effects on Vpr-dependent and Vpr-independent HIV-1 replication in macrophages. Blood 2004; 104: 1867–1872.
  CAS PubMed Google Scholar
• DeVico AL, Gallo RC . Control of HIV-1 infection by soluble factors of the immune response. Nat Rev Microbiol 2004; 2: 401–413.
  CAS PubMed Google Scholar
• Zhang L et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002; 298: 995–1000.
  CAS PubMed Google Scholar
• Zhang L et al. Retraction of an interpretation. Science 2004; 303: 467.
  CAS PubMed Google Scholar
• Chang TL et al. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. J Virol 2003; 77: 6777–6784.
  CAS PubMed PubMed Central Google Scholar
• Mackewicz CE, Craik CS, Levy JA . The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors. Proc Natl Acad Sci USA 2003; 100: 3433–3438.
  CAS PubMed PubMed Central Google Scholar
• Rugeles MT et al. Ribonuclease is partly responsible for the HIV-1 inhibitory effect activated by HLA alloantigen recognition. AIDS 2003; 17: 481–486.
  CAS PubMed Google Scholar
• Weiss RA . HIV and AIDS: looking ahead. Nat Med 2003; 9: 887–891.
  CAS PubMed PubMed Central Google Scholar
• Weiss RA . HIV and AIDS in relation to other pandemics. Among the viruses plaguing humans, HIV is a recent acquisition. Its outstanding success as an infection poses immense scientific challenges to human health and raises the question ‘What comes nest?’. EMBO Rep 2003; 4 (Spec No): S10–S14.
  CAS PubMed PubMed Central Google Scholar
• Global situation of the HIV/AIDS pandemic, end 2003. Part II: Estimating ARV global treatment needs (2003–2005). Wkly Epidemiol Rec 2003; 78: 426–430.
• UNAIDS report for 2003: most deaths and new infections ever; some good news. AIDS Treat News 2003; 396.
• Zarocostas J . WHO puts HIV/AIDS pandemic at top of its agenda. Lancet 2004; 363: 1615.
  PubMed Google Scholar
• Poluri A, Maanen MV, Sutton RE . Genetic therapy for HIV/AIDS. Expert Opin Biol Ther 2003; 3: 951–963.
  CAS PubMed Google Scholar